AbbVie (ABBV) is down -11.1%, or -$22.10 to $177.40.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Bristol Myers rises, AbbVie sinks after schizophrenia trials miss targets
- AbbVie’s emraclidine did not meet endpoint in Phase 2 schizophrenia trials
- AbbVie price target raised to $221 from $212 at Guggenheim
- AbbVie price target raised to $180 from $175 at Deutsche Bank
- Roblox, Peloton upgraded: Wall Street’s top analyst calls